Unclaimed brand
Tubulis is now part of Gilead Sciences www.gilead.com NEWS April 21 Tubulis to Present Phase I/IIa Trial Data for ADC Candidate TUB-040 in Platinum-resistant Ovarian Cancer in Rapid Oral Presentation at ASCO 2026 April 07 Gilead to Acquire Tubulis Adding Potentially Best-In-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline January 27 […]
Liking this brand profile? Share this page
Hex Code
Color name
RGB
HSL
CMYK
#FC4E1C
Orange
252, 78, 28
13, 97, 55
0, 69, 89, 1
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#262626
Mine Shaft
38, 38, 38
0, 0, 15
0, 0, 0, 85
Tubulis is a pioneering brand in the biotechnology industry, dedicated to revolutionizing antibody-drug conjugates (ADCs) for the treatment of cancer and other diseases. With a team of accomplished experts, Tubulis combines scientific innovation, strategic business development, and clinical expertise to develop cutting-edge therapies. Led by Dr.
Dominik Schumacher as the CEO, Tubulis has garnered recognition and prestigious start-up awards for its groundbreaking efforts. Dr. Jonas Helma-Smets serves as the Chief Scientific Officer, bringing over 10 years of experience in biotechnology and antibody engineering to the brand.
Dr. Ingo Lehrke, as the Chief Business Officer, contributes his 20 years of pharmaceutical industry experience and passion for strategic development. Dr.
Günter Fingerle-Rowson, the Chief Medical Officer, brings over 12 years of experience in clinical development and has successfully introduced novel drugs to cancer patients. Dr. Björn Hock, a seasoned expert in protein therapeutics and ADCs, serves as the Chief Development Officer on a consultant basis.
At Tubulis, their mission is to develop next-generation ADCs that specifically target cancer cells, maximizing efficacy while minimizing side effects. With a focus on protein therapeutics, Tubulis aims to improve the lives of patients by providing innovative treatment options. Their extensive pipeline of cutting-edge technologies showcases their commitment to advancing the field of biotechnology.
With a strong team of experts and a drive for scientific excellence, Tubulis is at the forefront of developing revolutionary therapies that have the potential to transform the future of medicine
Antibody-drug conjugates
P5 cysteine-selective conjugation
Topoisomerase I inhibitor ADCs
Targeted oncology therapeutics
Antibody degrader conjugates
